Cytovance Biologics Expands Analytical Services Portfolio with Standalone Capabilities

Editor’s Take: This unique approach provides access to an experienced analytical team and regulatory-ready solutions without a manufacturing attachment.

Cytovance Biologics is expanding its analytical services portfolio by offering standalone analytical capabilities for biotechnology and pharmaceutical clients. The CDMO says this builds on its more than 20 years’ experience supporting biologics development and manufacturing programs.

Crucially, the expansion allows for access to an experienced analytical team, and regulatory-ready solutions, without a manufacturing agreement in place. Customers can now engage Cytovance for analytical method development, transfer, qualification, validation, product characterization, release testing, stability studies, and storage.

Need for Standalone Services

As sponsors address growing demands for outsourced analytical support, this setup maintains flexibility in development and manufacturing strategies. Cytovance expects this demand to particularly grow within the United States.

Cytovance Biologics CEO Ping Zhang said limited resources, evolving regulatory requirements, and development pathways that are increasingly complex are roadblocks.

“Today’s biotechnology companies face increasing pressure to advance programs quickly,” Zhang said. “We are providing sponsors with access to experienced scientists, robust analytical capabilities, and quality-driven processes supporting informed decision-making throughout development. Our goal is to help clients move programs forward efficiently and with confidence.”

What Cytovance Promises

The standalone analytical services support early-stage development through commercialization, and are available in GMP (good manufacturing practice) and non-GMP environments. Sponsors can eventually leverage GMP-compliant testing and stability services from regulatory submissions through to process validation and commercial readiness.

Sudha Ankala, PhD, PMP, Cytovance Biologics Senior Director of Program Management, noted program requirements and development timelines are always evolving.

Ankala said Cytovance offers assistance “whether a sponsor requires a single analytical study, ongoing stability support, or routine GMP testing.”

“Our approach is centered on becoming a strategic analytical partner and an extension of our clients’ teams,” Ankala said.